Pieris Pharmaceuticals Inc
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut d… Read more
Pieris Pharmaceuticals Inc (PIRS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: 0.009x
Based on the latest financial reports, Pieris Pharmaceuticals Inc (PIRS) has a cash flow conversion efficiency ratio of 0.009x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($146.00K) by net assets ($16.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pieris Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2012–2023)
This chart illustrates how Pieris Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Pieris Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pieris Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Silvair Inc
WAR:SVRS
|
0.106x |
|
Pelangio Exploration Inc
PINK:PGXPF
|
-0.834x |
|
Jaya Agra Wattie Tbk
JK:JAWA
|
0.023x |
|
Betamek Bhd
KLSE:0263
|
0.023x |
|
UniPharma Co., Ltd.
TWO:6621
|
-0.112x |
|
FuelPositive Corp
OTCQB:NHHHF
|
0.001x |
|
AMJ Global Technology
PINK:AMJT
|
0.014x |
|
Arcure SA
PA:ALCUR
|
0.207x |
Annual Cash Flow Conversion Efficiency for Pieris Pharmaceuticals Inc (2012–2023)
The table below shows the annual cash flow conversion efficiency of Pieris Pharmaceuticals Inc from 2012 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $26.76 Million | $-53.82 Million | -2.011x | +6.27% |
| 2022-12-31 | $27.93 Million | $-59.93 Million | -2.146x | -1321.85% |
| 2021-12-31 | $50.76 Million | $-7.66 Million | -0.151x | +89.80% |
| 2020-12-31 | $31.03 Million | $-45.90 Million | -1.479x | -44.78% |
| 2019-12-31 | $51.35 Million | $-52.47 Million | -1.022x | -3727.59% |
| 2018-12-31 | $39.94 Million | $-1.07 Million | -0.027x | -100.62% |
| 2017-12-31 | $11.52 Million | $49.75 Million | 4.318x | +857.11% |
| 2016-12-31 | $25.23 Million | $-14.39 Million | -0.570x | -39.74% |
| 2015-12-31 | $31.13 Million | $-12.71 Million | -0.408x | -45.09% |
| 2014-12-31 | $18.01 Million | $-5.07 Million | -0.281x | +94.65% |
| 2013-12-31 | $585.01K | $-3.08 Million | -5.259x | +23.81% |
| 2012-12-31 | $1.32 Million | $-9.09 Million | -6.903x | -- |